This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
The Cancer Research Institute Associate Board is a group of young leaders dedicated to advancing cancer immunotherapy research. Members lend professional expertise and diverse talents to develop social events, assist with fundraising initiatives, and cultivate individual and corporate relationships.
CRI.ContactUs
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
In February 2017, Oswald became one of the first patients to receive pembrolizumab (Keytruda®) as first-line therapy for non-small cell lung cancer.
Dr. Kunle Odunsi discusses genomic testing, new treatments, and promising clinical trials in immunotherapy for ovarian cancer.